Previous 10 | Next 10 |
Legend Biotech (LEGN): Q3 GAAP EPS of -$0.25 misses by $0.01.Revenue of $11.74M (-33.6% Y/Y) misses by $2.26M.Press Release For further details see: Legend Biotech EPS misses by $0.01, misses on revenue
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial resu...
Legend Biotech (LEGN) appointed Ms. Ye (Sally) Wang, effective Nov.6, 2020 as Chairwoman of the Board.The board also named Dr. Ying Huang as CEO, effective Nov.6; Dr. Huang had been serving as interim CEO since Sep. 21, 2020.Quick look at the company's development pipeline...
Ye (Sally) Wang Appointed Chairwoman of the Board Ying Huang Named CEO Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapi...
New Results from Phase 1b/2 CARTITUDE-1 Study of BCMA-directed CAR-T Cell Therapy Cilta-cel in Treatment of Patients with RRMM to be Featured in Oral Presentation Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company en...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the Jefferies Virtual Cell Therapy Summit on Tuesday, Oc...
Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. Sequoia Capital China is raising $2.2 billion for a new yuan-denominated fund, the company's sixth fund. Sinovac Biotech ann...
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN ) investors concerning the Company’s possible violations of the federal securiti...
Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biot...
Shares of the Chinese anti-cancer cell therapy specialist Legend Biotech (NASDAQ: LEGN) are poised for a rough session today. Ahead of the opening bell Monday morning, the biotech's stock fell by as much as 15.8% in response to the news that the Customs Anti-Smuggling Department of ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...